Summary by Moomoo AI
Watanabe Todd Franklin completed a series of transactions involving Arcutis Biotherapeutics common stock. On 05/31/2024, he acquired 4,000 shares at $1.692 per share. Subsequently, on 11/30/2024, he purchased an additional 2,038 shares at $7.106 per share. The total number of shares acquired in these transactions was 6,038.Following these transactions, Watanabe's direct ownership of Arcutis Biotherapeutics shares increased to 838,430. The transactions were conducted as open market or private purchases. Additionally, Watanabe holds 231,140 shares indirectly through trusts and an LLC.These transactions reflect Watanabe's continued investment in Arcutis Biotherapeutics, with the latest acquisition completed on 11/30/2024. The transactions are now finalized, with no shares disposed of during this period.
